1. Home
  2. XOMAO vs NPV Comparison

XOMAO vs NPV Comparison

Compare XOMAO & NPV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XOMAO
  • NPV
  • Stock Information
  • Founded
  • XOMAO N/A
  • NPV 1993
  • Country
  • XOMAO United States
  • NPV United States
  • Employees
  • XOMAO 13
  • NPV N/A
  • Industry
  • XOMAO Biotechnology: Pharmaceutical Preparations
  • NPV Investment Managers
  • Sector
  • XOMAO Health Care
  • NPV Finance
  • Exchange
  • XOMAO Nasdaq
  • NPV Nasdaq
  • Market Cap
  • XOMAO N/A
  • NPV N/A
  • IPO Year
  • XOMAO N/A
  • NPV N/A
  • Fundamental
  • Price
  • XOMAO $25.39
  • NPV $11.93
  • Analyst Decision
  • XOMAO
  • NPV
  • Analyst Count
  • XOMAO 0
  • NPV 0
  • Target Price
  • XOMAO N/A
  • NPV N/A
  • AVG Volume (30 Days)
  • XOMAO N/A
  • NPV 38.9K
  • Earning Date
  • XOMAO N/A
  • NPV 01-01-0001
  • Dividend Yield
  • XOMAO N/A
  • NPV 3.90%
  • EPS Growth
  • XOMAO N/A
  • NPV N/A
  • EPS
  • XOMAO N/A
  • NPV N/A
  • Revenue
  • XOMAO N/A
  • NPV N/A
  • Revenue This Year
  • XOMAO N/A
  • NPV N/A
  • Revenue Next Year
  • XOMAO N/A
  • NPV N/A
  • P/E Ratio
  • XOMAO N/A
  • NPV N/A
  • Revenue Growth
  • XOMAO N/A
  • NPV N/A
  • 52 Week Low
  • XOMAO N/A
  • NPV $8.92
  • 52 Week High
  • XOMAO N/A
  • NPV $11.55
  • Technical
  • Relative Strength Index (RSI)
  • XOMAO 52.06
  • NPV 19.85
  • Support Level
  • XOMAO $25.42
  • NPV $12.10
  • Resistance Level
  • XOMAO $25.46
  • NPV $12.40
  • Average True Range (ATR)
  • XOMAO 0.05
  • NPV 0.09
  • MACD
  • XOMAO 0.00
  • NPV -0.02
  • Stochastic Oscillator
  • XOMAO 79.10
  • NPV 0.00

About XOMAO AGNC Investment Corp.

XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

Share on Social Networks: